ORY.MC WACC - Weighted Average Cost of Capital
The WACC of Oryzon Genomics SA (ORY.MC) is 10.9%.
| Range | Selected | |
| Cost of equity | 9.3% - 13.3% | 11.3% |
| Tax rate | 34.5% - 35.0% | 34.75% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 9.0% - 12.8% | 10.9% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 7.4% | 8.4% |
| Adjusted beta | 0.84 | 1.09 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 9.3% | 13.3% |
| Tax rate | 34.5% | 35.0% |
| Debt/Equity ratio | 0.05 | 0.05 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 9.0% | 12.8% |
| Selected WACC | 10.9% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| ORY.MC | Oryzon Genomics SA | 0.05 | 0.72 | 0.69 |
| ABVX.PA | Abivax SA | 0.25 | 1.68 | 1.45 |
| ALSEN.PA | Sensorion SA | 0.02 | 1.42 | 1.4 |
| DMYD B.ST | Diamyd Medical AB | 0.03 | 0.11 | 0.11 |
| FARN.L | Faron Pharmaceuticals Oy | 0.04 | 1.13 | 1.1 |
| MDXH.BR | MDxHealth SA | 0.44 | 1.88 | 1.47 |
| SCLP.L | Scancell Holdings PLC | 0.19 | -0.09 | -0.08 |
| TILS.L | Tiziana Life Sciences PLC | 0.01 | -1.34 | -1.34 |
| XBRANE.ST | Xbrane Biopharma AB | 0.62 | 1.07 | 0.77 |
| XSPRAY.ST | XSpray Pharma AB (publ) | 0.13 | 1.19 | 1.1 |
| Low | High | |
| Unlevered beta | 0.74 | 1.1 |
| Relevered beta | 0.76 | 1.13 |
| Adjusted relevered beta | 0.84 | 1.09 |
ORY.MC's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ORY.MC:
cost_of_equity (11.30%) = risk_free_rate (3.35%) + equity_risk_premium (7.90%) * adjusted_beta (0.84) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.